Compare Medpace Holdings Inc (MEDP) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Boston Beer Company Inc — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.87B), while Boston Beer Company Inc trades at $171.63 (market cap $1.73B). The key difference: Medpace Holdings Inc is far larger — about 9.8× Boston Beer Company Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Boston Beer Company Inc for 59 Days on average.
| MEDP | SAM | |
|---|---|---|
Market Cap | $16.87B | $1.73B |
Volume | 207,570 | 196,621 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $260.05 |
52-Week Low | $393.42 | $161.08 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | $16.48B | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Boston Beer Company (SAM) trades at $168.16, down 1.3% with a neutral technical outlook. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.92, but negative net income margin of -3.64% and ROE of -8.61%. Recent earnings missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains positive operating cash flow of $270M in 2025 while expanding brand innovation with new product launches and marketing initiatives.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product categories offer growth potential. Analyst consensus is cautious with 72% hold ratings, though the $204.44 price target suggests 22% upside. Key risks include competitive pressures and shifting consumer preferences in the alcoholic beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
